James is a neuroscientist with over 10 years of experience in studying rare neurodevelopmental disorders. His background and expertise include electrophysiology, synaptic function and plasticity, and stem cell-derived neuron differentiation. James received his Ph.D. from the University of Connecticut, where he used patient neuronal models of Angelman syndrome and Dup15q syndrome to explore the roles of UBE3A in neuronal function to identify in vitro phenotypes that could be used for drug screening. He joined Q-State (now Quiver Bioscience) in 2018 and has spent the last 8 years using all-optical electrophysiology and human cellular models to derive insights into several CNS disorders including Rett syndrome, Fragile X syndrome, and Phelan-McDermid (SHANK) syndrome. Currently at Quiver Bioscience, he leads antisense oligonucleotide programs for Dup15q syndrome and other neurodevelopmental disorders.